{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:56:38Z","timestamp":1789908998736,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1124\/jpet.116.235952","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T01:10:23Z","timestamp":1479431423000},"page":"313-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid \u03b1-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease"],"prefix":"10.1016","volume":"360","author":[{"given":"Jeffrey","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Haroldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Cahayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie S.","family":"Tsuruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.235952_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol"},{"key":"10.1124\/jpet.116.235952_bib2","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235952_bib3","first-page":"42","article-title":"Glycogen storage disease type II: clinical overview","volume":"26","author":"Di Rocco","year":"2007","journal-title":"Acta Myol"},{"key":"10.1124\/jpet.116.235952_bib4","series-title":"Myozyme: EPAR- Scientific Discussion","author":"European Medicines","year":"2007"},{"key":"10.1124\/jpet.116.235952_bib5","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.116.235952_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.116.235952_bib7","series-title":"Guidance For Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","year":"2005"},{"key":"10.1124\/jpet.116.235952_bib8","series-title":"Product Development under the Animal Rule: Guidance for Industry","year":"2015"},{"key":"10.1124\/jpet.116.235952_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1124\/jpet.116.235952_bib10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.nmd.2015.09.003","article-title":"Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: New insights from a comparative study by MRI and respiratory function assessment","volume":"25","author":"Gaeta","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1124\/jpet.116.235952_bib11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ymgme.2012.05.007","article-title":"Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature","volume":"106","author":"Hobson-Webb","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1124\/jpet.116.235952_bib12","unstructured":"International Conference on Harmonisation\u2026 (2007) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2), The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Multidisciplinary\/M3_R2\/Step4\/M3_R2__Guideline.pdf."},{"key":"10.1124\/jpet.116.235952_bib13","series-title":"An Improved Alpha-Glucosidase Enzyme for Pompe Disease","author":"Kakkis","year":"2008"},{"key":"10.1124\/jpet.116.235952_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1124\/jpet.116.235952_bib15","series-title":"Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists","first-page":"220","author":"Kwon","year":"2001"},{"key":"10.1124\/jpet.116.235952_bib16","series-title":"SAS for Mixed Models, 2nd ed","author":"Littell","year":"2006"},{"key":"10.1124\/jpet.116.235952_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/002215540505300108","article-title":"High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology","volume":"53","author":"Lynch","year":"2005","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/jpet.116.235952_bib18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235952_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1124\/jpet.116.235952_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rmed.2008.12.009","article-title":"Pompe disease: a neuromuscular disease with respiratory muscle involvement","volume":"103","author":"Mellies","year":"2009","journal-title":"Respir Med"},{"key":"10.1124\/jpet.116.235952_bib21","unstructured":"Myozyme (2014) Package insert. Genzyme Corporation, Framingham, MA."},{"key":"10.1124\/jpet.116.235952_bib22","unstructured":"National Research Council (2011) Guide for the Care and Use of Laboratory Animals, 8th ed. Institute for Laboratory Animal Research, Division on Earth and Life Studies."},{"key":"10.1124\/jpet.116.235952_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1124\/jpet.116.235952_bib25","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235952_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1124\/jpet.116.235952_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe Disease","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.116.235952_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6neo\/6neo Pompe disease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/jpet.116.235952_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1124\/jpet.116.235952_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"issue":"2","key":"10.1124\/jpet.116.235952_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.24433","article-title":"Correcting neuromuscular deficits with gene therapy in Pompe disease","volume":"78","author":"Todd","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.116.235952_bib30","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1016\/S0021-9258(18)83137-4","article-title":"Ligand interactions of the cation-dependent mannose 6-phosphate receptor. Comparison with the cation-independent mannose 6-phosphate receptor","volume":"264","author":"Tong","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235952_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.resp.2016.02.007","article-title":"Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(-\/-)) mice","volume":"227","author":"Turner","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1124\/jpet.116.235952_bib32","first-page":"82","article-title":"Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy","volume":"106","author":"van der Beek","year":"2006","journal-title":"Acta Neurol Belg"},{"key":"10.1124\/jpet.116.235952_bib33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.116.235952_bib34","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/jpet.116.235952_bib35","series-title":"The Animal Welfare Act and Animal Welfare Regulations","year":"2013"},{"key":"10.1124\/jpet.116.235952_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00408-013-9489-x","article-title":"Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency","volume":"191","author":"Vianello","year":"2013","journal-title":"Lung"},{"key":"10.1124\/jpet.116.235952_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12890-015-0058-3","article-title":"Lung MRI and impairment of diaphragmatic function in Pompe disease","volume":"15","author":"Wens","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1124\/jpet.116.235952_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.235952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:51:32Z","timestamp":1739994692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524194979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0022356524194979"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.235952","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid \u03b1-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.235952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}